Japan's Takeda accelerates dengue vaccine access through manufacturing partnership with Biological E in India
Singapore, Feb. 27 -- Japanese pharmaceutical company Takeda has announced a strategic partnership with Biological E, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003.
The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030.
The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 millio...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.